Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.67 |
| ▸ | GAA | P10253 | 1/20 | 0.67 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.51 |
| ▸ | MEN1 | O00255 | 3/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | BRD4 | O60885 | 1/20 | 0.41 |
| ▸ | METAP2 | P50579 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL402314 | 0.85 | SMN1; SMN2 (0.58) | L3MBTL1GAASMN1; SMN2KMT2AMEN1 | |
| SCHEMBL30782812 | 0.80 | KMT2A (0.54) | L3MBTL1GAASMN1; SMN2KMT2AMEN1 | |
| SCHEMBL3211065 | 0.75 | NPC1 (0.54) | L3MBTL1GAASMN1; SMN2KMT2AALDH1A1 | |
| SCHEMBL10938557 | 0.73 | ALDH1A1 (0.64) | ALDH1A1NPC1MAPTMETAP2 | |
| SCHEMBL11817098 | 0.71 | APEX1 (0.53) | SMN1; SMN2ALDH1A1NPC1CYP3A4POLB | |
| SCHEMBL30423190 | 0.71 | APEX1 (0.53) | SMN1; SMN2ALDH1A1NPC1CYP3A4POLB | |
| SCHEMBL3187786 | 0.71 | L3MBTL1 (0.44) | L3MBTL1GAASMN1; SMN2KMT2AMEN1 | |
| SCHEMBL12490893 | 0.70 | NPC1 (0.56) | L3MBTL1KMT2AMEN1NPC1POLB | |
| SCHEMBL3084334 | 0.68 | NPC1 (0.68) | GAASMN1; SMN2KMT2AMEN1ALDH1A1 | |
| SCHEMBL3191046 | 0.68 | L3MBTL1 (0.61) | L3MBTL1GAASMN1; SMN2KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9045418-B2 | Compounds, compositions and methods for treatment and prevention of Orthopoxvirus infections and associated diseases | SIGA TECHNOLOGIES, INC. (US) | 2015-06-02 | — | — | US | disclosed |
| US-20140316145-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATMENT AND PREVENTION OF ORTHOPOXVIRUS INFECTIONS AND ASSOCIATED DISEASES | SIGA TECHNOLOGIES, INC., (US) | 2014-10-23 | — | — | US | disclosed |
| US-8802714-B2 | Compounds, compositions and methods for treatment and prevention of orthopoxvirus infections and associated diseases | SIGA TECHNOLOGIES, INC. (US) | 2014-08-12 | — | — | US | disclosed |
| US-20130345278-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATMENT AND PREVENTION OF ORTHOPOXVIRUS INFECTIONS AND ASSOCIATED DISEASES | SIGA TECHNOLOGIES, INC. (US) | 2013-12-26 | — | — | US | disclosed |
| US-8530509-B2 | Compounds, compositions and methods for treatment and prevention of orthopoxvirus infections and associated diseases | SIGA TECHNOLOGIES, INC. (US) | 2013-09-10 | — | — | US | disclosed |
| US-8124643-B2 | Compounds, compositions and methods for treatment and prevention of orthopoxvirus infections and associated diseases | SIGA TECHNOLOGIES, INC. (US) | 2012-02-28 | — | — | US | disclosed |
| US-20120020922-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATMENT AND PREVENTION OF ORTHOPOXVIRUS INFECTIONS AND ASSOCIATED DISEASES | SIGA TECHNOLOGIES INC. (US) | 2012-01-26 | — | — | US | disclosed |
| US-8039504-B2 | heating a mixture of anti-tricyclo[3.2.2.0]non-6-ene-endo-8, endo-9-dicarboxylic acid anhydride, 4-(trifluoromethyl)benzhydrazide, and ethanol at reflux, concetrating and recrystallizing; 4-Trifluoromethyl-N- (3,3a,4,4a,5,5a,6,6a,- octahydro-1,3-dioxo-4,6- ethenocycloprop[f]isoindol- 2(1H)-yl)-benzamide | SIGA TECHNOLOGIES, INC. (US) | 2011-10-18 | — | — | US | disclosed |
| US-7956197-B2 | Compounds, compositions and methods for treatment and prevention of orthopoxvirus infections and associated diseases | SIGA TECHNOLOGIES, INC. (US) | 2011-06-07 | — | — | US | disclosed |
| US-20110009456-A1 | Compounds, Compositions and Methods for Treatment and Prevention of Orthopoxvirus Infections and Associated Diseases | SIGA TECHNOLOGIES INC. (US) | 2011-01-13 | — | — | US | disclosed |
| US-20100227892-A1 | Compounds, Compositions and Methods for Treatment and Prevention of Orthopoxvirus Infections and Associated Diseases | SIGA TECHNOLOGIES INC. (US) | 2010-09-09 | — | — | US | disclosed |
| US-7737168-B2 | Compounds, compositions, and methods for treatment and prevention of orthopoxvirus infections and associated diseases | SIGA TECHNOLOGIES, INC. (US) | 2010-06-15 | — | — | US | disclosed |
| EP-2192901-A2 | CHEMICALS, COMPOSITIONS, AND METHODS FOR TREATMENT AND PREVENTION OF ORTHOPOXVIRUS INFECTIONS AND ASSOCIATED DISEASES | SIGA TECHNOLOGIES, INC. (US) | 2010-06-09 | — | — | EP | disclosed |
| US-7687641-B2 | Chemicals, compositions, and methods for treatment and prevention of orthopoxvirus infections and associated diseases | SIGA TECHNOLOGIES, INC. (US) | 2010-03-30 | — | — | US | disclosed |
| WO-2008079159-A2 | CHEMICALS, COMPOSITIONS, AND METHODS FOR TREATMENT AND PREVENTION OF ORTHOPOXVIRUS INFECTIONS AND ASSOCIATED DISEASES | SIGA TECHNOLOGIES, INC. (US) | 2008-07-03 | — | — | WO | disclosed |
| US-20080103181-A9 | Compounds, compositions, and methods for treatment and prevention of orthopoxvirus infections and associated diseases | SIGA TECHNOLOGIES, INC. (US) | 2008-05-01 | — | — | US | disclosed |
| US-20080004452-A1 | Chemicals, compositions, and methods for treatment and prevention of orthopoxvirus infections and associated diseases | SIGA TECHNOLOGIES, INC. (US) | 2008-01-03 | — | — | US | disclosed |
| US-20070287735-A1 | Chemicals, compositions, and methods for treatment and prevention of orthopoxvirus infections and associated diseases | SIGA TECHNOLOGIES, INC. (US) | 2007-12-13 | — | — | US | disclosed |
| US-20060235051-A1 | Compounds, compositions, and methods for treatment and prevention of orthopoxvirus infections and associated diseases | SIGA TECHNOLOGIES, INC. (US) | 2006-10-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070287735-A1 | Chemicals, compositions, and methods for treatment and prevention of orthopoxvirus infections and associated diseases | OTC, FAHD1, OAT | L3MBTL1 1899/4885GAA 239/4885SMN1; SMN2 3328/4885 |
| US-20060235051-A1 | Compounds, compositions, and methods for treatment and prevention of orthopoxvirus infections and associated diseases | OTC, FAHD1, OAT | L3MBTL1 1630/4885GAA 141/4885SMN1; SMN2 2395/4885 |
| US-20100227892-A1 | Compounds, Compositions and Methods for Treatment and Prevention of Orthopoxvirus Infections and Associated Diseases | OTC, FAHD1, VAC14 | L3MBTL1 2051/4885GAA 127/4885SMN1; SMN2 2623/4885 |
| US-20080103181-A9 | Compounds, compositions, and methods for treatment and prevention of orthopoxvirus infections and associated diseases | OTC, FAHD1, OAT | L3MBTL1 1630/4885GAA 141/4885SMN1; SMN2 2395/4885 |
| US-20080004452-A1 | Chemicals, compositions, and methods for treatment and prevention of orthopoxvirus infections and associated diseases | OTC, FAHD1, OAT | L3MBTL1 1899/4885GAA 239/4885SMN1; SMN2 3328/4885 |
| US-20110009456-A1 | Compounds, Compositions and Methods for Treatment and Prevention of Orthopoxvirus Infections and Associated Diseases | OTC, FAHD1, VAC14 | L3MBTL1 2051/4885GAA 127/4885SMN1; SMN2 2623/4885 |
| US-20140316145-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATMENT AND PREVENTION OF ORTHOPOXVIRUS INFECTIONS AND ASSOCIATED DISEASES | OTC, FAHD1, VAC14 | L3MBTL1 2051/4885GAA 127/4885SMN1; SMN2 2623/4885 |
| US-20120020922-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATMENT AND PREVENTION OF ORTHOPOXVIRUS INFECTIONS AND ASSOCIATED DISEASES | OTC, FAHD1, VAC14 | L3MBTL1 2051/4885GAA 127/4885SMN1; SMN2 2623/4885 |
| US-20130345278-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATMENT AND PREVENTION OF ORTHOPOXVIRUS INFECTIONS AND ASSOCIATED DISEASES | OTC, FAHD1, VAC14 | L3MBTL1 2051/4885GAA 127/4885SMN1; SMN2 2623/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.